Serious Adverse Events with Bevacizumab or Ranibizumab for Age-related Macular Degeneration: Meta-analysis of Individual Patient Data.

ABSTRACT:

Topic

A comparison between ranibizumab and bevacizumab of the incidence of systemic serious adverse events (SAEs) among patients with neovascular age-related macular degeneration (nAMD) who participated in a large-scale randomized trial. Use of individual patient data, rather than aggregate data, allowed adjustment for strong predictors of SAEs.

Clinical relevance

Relative safety of ranibizumab and bevacizumab is important in choosing an anti-VEGF drug for the hundreds of thousands of patients with nAMD treated each year worldwide.

Methods

Results of a Cochrane aggregate meta-analysis of the relative efficacy and safety of bevacizumab and ranibizumab that used searches of bibliographic databases and clinical trial registries as of March 14, 2014 and hand searching wer

SUBMITTER: Bevacizumab-Ranibizumab International Trials Group 

PROVIDER: S-EPMC5640431 | biostudies-literature | 2017 Sep-Oct

REPOSITORIES: biostudies-literature